Opdualag is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
nivolumab and relatlimab are produced in CHOcells.
Both drugs are (ICIs) immune checkpoint inhibitors, which target proteins called checkpoints that help stop the immune system from mounting a strong response against cancer cells. Relatlimab blocks a protein on immune cells called LAG-3, while nivolumab blocks a different protein on immune cells called PD-1. By blocking these proteins, these drugs can unleash an immune response against cancer cells.
Are you involved in R&D on antibodies ?
Are you planning to screen different protein variants?
👉We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
